Insider Transactions in Q4 2024 at Genelux Corp (GNLX)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2024
|
James L Tyree |
SELL
Open market or private sale
|
Direct |
3,460
-7.03%
|
$6,920
$2.46 P/Share
|
|
Dec 18
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,650
+33.56%
|
-
|
|
Dec 18
2024
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+39.92%
|
-
|
|
Dec 18
2024
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+42.11%
|
-
|
|
Dec 18
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+34.71%
|
-
|
|
Dec 18
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
15,525
+32.77%
|
-
|
|
Dec 18
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
134,500
+43.9%
|
-
|
|
Dec 16
2024
|
Joseph Cappello VP, Pharmaceutical Development |
SELL
Open market or private sale
|
Direct |
6,300
-30.07%
|
$12,600
$2.34 P/Share
|
|
Dec 16
2024
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
2,510
-13.33%
|
$5,020
$2.34 P/Share
|
|
Dec 16
2024
|
Lourie S. Zak Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,103
-4.9%
|
$4,206
$2.34 P/Share
|
|
Dec 16
2024
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
14,315
-27.7%
|
$28,630
$2.34 P/Share
|